Resolution Therapeutics – a private biotech focused on macrophage-based cell therapies – saw a week of heightened scientific and corporate visibility as it advanced RTX001, its lead regenerative macrophage therapy for end-stage liver disease. This recap summarizes the company’s key announcements and activities over the past week.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company highlighted that RTX001 is being evaluated in the Phase I/II EMERALD trial for patients with end-stage liver disease, with sites in the U.K. and Spain and an interim cohort now fully enrolled. An interim data readout is targeted for late 2026, and earlier data expected later this year have been framed as potential clinical and valuation catalysts.
Resolution Therapeutics plans a notable scientific presence at major industry meetings, signaling continued progress for RTX001. At the American Society of Gene & Cell Therapy 29th Annual Meeting in Boston, Senior Vice President and Head of Research and Translational Science Lara Campana is scheduled to present preclinical data in a session on novel T-cell and myeloid strategies.
In parallel, co-founder Professor Stuart Forbes will deliver a plenary presentation on macrophage therapy for liver disease at the ISCT 2026 meeting in Dublin, underscoring three decades of work on macrophages in liver fibrosis and regeneration. These appearances emphasize the scientific foundation behind RTX001 and highlight growing interest in macrophage-based approaches within the broader cell and gene therapy field.
Beyond scientific conferences, Resolution’s senior clinical leaders plan to attend Digestive Disease Week in Chicago to engage hepatology and gastroenterology experts and potential partners. The company also increased its profile through participation in the Advanced Therapies Congress and the Anglonordic Life Science Conference, aligning outreach with World Liver Day to stress the unmet need in liver disease.
Operationally, Resolution strengthened its leadership by appointing Louise Rowe as vice president of operations, adding experience in cell and gene therapy development. The firm is investing in scalable, AI- and automation-enabled manufacturing and supply chain capabilities and noted external recognition of its VP of IP & Technology Strategy in a global in-house legal ranking.
The company also highlighted a proactive approach to regulatory strategy, with VP of Analytical Development Damian Marshall joining a panel alongside Roche Genentech and Cabaletta Bio on evolving FDA and EMA expectations. Emphasizing early regulatory planning, CDMO oversight, and organizational agility may help align programs with current guidance and potentially reduce approval risks and timelines.
Taken together, this week’s developments suggest building momentum for Resolution Therapeutics as it advances RTX001 through early clinical testing while reinforcing its scientific credibility, operational readiness, and regulatory positioning, setting the stage for upcoming EMERALD trial readouts.